Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.

Guidi M, Mercier T, Aouri M, Decosterd LA, Csajka C, Ogutu B, Carn G, Kiechel JR.

Malar J. 2019 Apr 18;18(1):139. doi: 10.1186/s12936-019-2754-6.

2.

Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing.

Ali AM, Penny MA, Smith TA, Workman L, Sasi P, Adjei GO, Aweeka F, Kiechel JR, Jullien V, Rijken MJ, McGready R, Mwesigwa J, Kristensen K, Stepniewska K, Tarning J, Barnes KI, Denti P; WWARN Amodiaquine PK Study Group.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e02193-17. doi: 10.1128/AAC.02193-17. Print 2018 Oct.

3.

Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.

Otienoburu SD, Maïga-Ascofaré O, Schramm B, Jullien V, Jones JJ, Zolia YM, Houzé P, Ashley EA, Kiechel JR, Guérin PJ, Le Bras J, Houzé S.

Malar J. 2016 Sep 5;15:452. doi: 10.1186/s12936-016-1503-3.

4.

Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults.

Petit C, Jullien V, Samson A, Guedj J, Kiechel JR, Zohar S, Comets E.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1481-91. doi: 10.1128/AAC.01125-15.

5.

The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data.

WorldWide Antimalarial Resistance Network (WWARN) AS-AQ Study Group, Adjuik MA, Allan R, Anvikar AR, Ashley EA, Ba MS, Barennes H, Barnes KI, Bassat Q, Baudin E, Björkman A, Bompart F, Bonnet M, Borrmann S, Brasseur P, Bukirwa H, Checchi F, Cot M, Dahal P, D'Alessandro U, Deloron P, Desai M, Diap G, Djimde AA, Dorsey G, Doumbo OK, Espié E, Etard JF, Fanello CI, Faucher JF, Faye B, Flegg JA, Gaye O, Gething PW, González R, Grandesso F, Guerin PJ, Guthmann JP, Hamour S, Hasugian AR, Hay SI, Humphreys GS, Jullien V, Juma E, Kamya MR, Karema C, Kiechel JR, Kremsner PG, Krishna S, Lameyre V, Ibrahim LM, Lee SJ, Lell B, Mårtensson A, Massougbodji A, Menan H, Ménard D, Menéndez C, Meremikwu M, Moreira C, Nabasumba C, Nambozi M, Ndiaye JL, Nikiema F, Nsanzabana C, Ntoumi F, Ogutu BR, Olliaro P, Osorio L, Ouédraogo JB, Penali LK, Pene M, Pinoges L, Piola P, Price RN, Roper C, Rosenthal PJ, Rwagacondo CE, Same-Ekobo A, Schramm B, Seck A, Sharma B, Sibley CH, Sinou V, Sirima SB, Smith JJ, Smithuis F, Somé FA, Sow D, Staedke SG, Stepniewska K, Swarthout TD, Sylla K, Talisuna AO, Tarning J, Taylor WR, Temu EA, Thwing JI, Tjitra E, Tine RC, Tinto H, Vaillant MT, Valecha N, Van den Broek I, White NJ, Yeka A, Zongo I.

BMC Med. 2015 Mar 31;13:66. doi: 10.1186/s12916-015-0301-z.

6.

A Randomized Trial to Compare the Safety, Tolerability, and Effectiveness of 3 Antimalarial Regimens for the Prevention of Malaria in Nigerian Patients With Sickle Cell Disease.

Olaosebikan R, Ernest K, Bojang K, Mokuolu O, Rehman AM, Affara M, Nwakanma D, Kiechel JR, Ogunkunle T, Olagunju T, Murtala R, Omefe P, Lambe T, Bello S, Ibrahim O, Olorunsola B, Ojuawo A, Greenwood B, Milligan P.

J Infect Dis. 2015 Aug 15;212(4):617-25. doi: 10.1093/infdis/jiv093. Epub 2015 Feb 20.

7.

Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine.

Ogutu B, Juma E, Obonyo C, Jullien V, Carn G, Vaillant M, Taylor WR, Kiechel JR.

Malar J. 2014 Dec 16;13:498. doi: 10.1186/1475-2875-13-498.

8.

Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.

Bouazza N, Foissac F, Fauchet F, Burger D, Kiechel JR, Treluyer JM, Capparelli EV, Lallemant M, Urien S.

Antivir Ther. 2015;20(2):225-33. doi: 10.3851/IMP2876. Epub 2014 Oct 3.

PMID:
25279808
9.

Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.

Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price RN, Mårtensson A, Rosenthal PJ, Dorsey G, Sutherland CJ, Guérin P, Davis TME, Ménard D, Adam I, Ademowo G, Arze C, Baliraine FN, Berens-Riha N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimdé AA, El-Sayed BB, Eshetu T, Eyase F, Falade C, Faucher JF, Fröberg G, Grivoyannis A, Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel JR, Kironde F, Kofoed PE, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya SL, Nzila A, Oguike M, Otienoburu SD, Ogutu B, Ouédraogo JB, Piola P, Rombo L, Schramm B, Somé AF, Thwing J, Ursing J, Wong RPM, Zeynudin A, Zongo I, Plowe CV, Sibley CH, Asaq Molecular Marker Study Group.

Am J Trop Med Hyg. 2014 Oct;91(4):833-843. doi: 10.4269/ajtmh.14-0031. Epub 2014 Jul 21. Erratum in: Am J Trop Med Hyg. 2015 May;92(5):1084. Am J Trop Med Hyg. 2019 Mar;100(3):766.

10.
11.

Safety, efficacy and population pharmacokinetics of fixed-dose combination of artesunate-mefloquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in India.

Valecha N, Srivastava B, Dubhashi NG, Rao BH, Kumar A, Ghosh SK, Singh JP, Kiechel JR, Sharma B, Jullien V, Dash AP, Taylor WR, Anvikar AR.

J Vector Borne Dis. 2013 Dec;50(4):258-64.

12.

Therapeutic efficacy of fixed dose artesunate-mefloquine for the treatment of acute, uncomplicated Plasmodium falciparum malaria in Kampong Speu, Cambodia.

Leang R, Ros S, Duong S, Navaratnam V, Lim P, Ariey F, Kiechel JR, Ménard D, Taylor WR.

Malar J. 2013 Sep 23;12:343. doi: 10.1186/1475-2875-12-343.

13.

Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial.

Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, Dhorda M, Boum Y 2nd, Sundaygar T, Zolia YM, Jones JJ, Comte E, Houzé P, Jullien V, Carn G, Kiechel JR, Ashley EA, Guérin PJ.

Malar J. 2013 Jul 17;12:251. doi: 10.1186/1475-2875-12-251.

14.

Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia.

Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, Sundaygar T, Zolia YM, Jones JJ, Comte E, Bruneel A, Branger M, Jullien V, Carn G, Kiechel JR, Ashley EA, Guérin PJ.

Malar J. 2013 Jul 17;12:250. doi: 10.1186/1475-2875-12-250.

15.

The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: case study.

Wells S, Diap G, Kiechel JR.

Malar J. 2013 Feb 21;12:68. doi: 10.1186/1475-2875-12-68.

16.

Access to artemisinin-combination therapy (ACT) and other anti-malarials: national policy and markets in Sierra Leone.

Amuasi JH, Diap G, Nguah SB, Karikari P, Boakye I, Jambai A, Lahai WK, Louie KS, Kiechel JR.

PLoS One. 2012;7(10):e47733. doi: 10.1371/journal.pone.0047733. Epub 2012 Oct 25.

17.

Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India.

Anvikar AR, Sharma B, Shahi BH, Tyagi PK, Bose TK, Sharma SK, Srivastava P, Srivastava B, Kiechel JR, Dash AP, Valecha N.

Malar J. 2012 Mar 30;11:97. doi: 10.1186/1475-2875-11-97.

18.

Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience.

Bompart F, Kiechel JR, Sebbag R, Pecoul B.

Malar J. 2011 May 23;10:143. doi: 10.1186/1475-2875-10-143.

19.

The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership.

Lacaze C, Kauss T, Kiechel JR, Caminiti A, Fawaz F, Terrassin L, Cuart S, Grislain L, Navaratnam V, Ghezzoul B, Gaudin K, White NJ, Olliaro PL, Millet P.

Malar J. 2011 May 23;10:142. doi: 10.1186/1475-2875-10-142.

20.

Access to artesunate-amodiaquine, quinine and other anti-malarials: policy and markets in Burundi.

Amuasi JH, Diap G, Blay-Nguah S, Boakye I, Karikari PE, Dismas B, Karenzo J, Nsabiyumva L, Louie KS, Kiechel JR.

Malar J. 2011 Feb 10;10:34. doi: 10.1186/1475-2875-10-34.

21.

Effect of artesunate and mefloquine in combination on the Fridericia corrected QT intervals in Plasmodium falciparum infected adults from Thailand.

Krudsood S, Looareesuwan S, Wilairatama P, Leowattana W, Tangpukdee N, Chalermrut K, Ramanathan S, Navaratnam V, Olliaro P, Vaillant M, Kiechel JR, Taylor WR.

Trop Med Int Health. 2011 Apr;16(4):458-65. doi: 10.1111/j.1365-3156.2010.02714.x. Epub 2011 Jan 10.

22.

New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine.

Krudsood S, Looareesuwan S, Tangpukdee N, Wilairatana P, Phumratanaprapin W, Leowattana W, Chalermrut K, Ramanathan S, Navaratnam V, Olliaro P, Vaillant M, Kiechel JR, Taylor WR.

Antimicrob Agents Chemother. 2010 Sep;54(9):3730-7. doi: 10.1128/AAC.01187-09. Epub 2010 Jun 14. Erratum in: Antimicrob Agents Chemother. 2010 Oct;54(10):4526.

23.

Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.

Jullien V, Ogutu B, Juma E, Carn G, Obonyo C, Kiechel JR.

Antimicrob Agents Chemother. 2010 Jun;54(6):2611-7. doi: 10.1128/AAC.01496-09. Epub 2010 Apr 5.

24.

Population pharmacokinetics of artesunate and amodiaquine in African children.

Stepniewska K, Taylor W, Sirima SB, Ouedraogo EB, Ouedraogo A, Gansané A, Simpson JA, Morgan CC, White NJ, Kiechel JR.

Malar J. 2009 Aug 20;8:200. doi: 10.1186/1475-2875-8-200.

25.

Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers.

Navaratnam V, Ramanathan S, Wahab MS, Siew Hua G, Mansor SM, Kiechel JR, Vaillant M, Taylor WR, Olliaro P.

Eur J Clin Pharmacol. 2009 Aug;65(8):809-21. doi: 10.1007/s00228-009-0656-1. Epub 2009 Apr 30.

26.

The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum.

Sirima SB, Tiono AB, Gansané A, Diarra A, Ouédraogo A, Konaté AT, Kiechel JR, Morgan CC, Olliaro PL, Taylor WR.

Malar J. 2009 Mar 16;8:48. doi: 10.1186/1475-2875-8-48.

27.

[ASAQ, a breakthrough in the fight against malaria].

Kiechel JR, Pécoul B.

Med Trop (Mars). 2007 Apr;67(2):109-10. French. No abstract available.

PMID:
17691424
28.

Fluoronaphthyridines and -quinolones as antibacterial agents. 5. Synthesis and antimicrobial activity of chiral 1-tert-butyl-6-fluoro-7-substituted-naphthyridones.

Di Cesare P, Bouzard D, Essiz M, Jacquet JP, Ledoussal B, Kiechel JR, Remuzon P, Kessler RE, Fung-Tomc J, Desiderio J.

J Med Chem. 1992 Oct 30;35(22):4205-13.

PMID:
1433222
30.

Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.

Bouzard D, Di Cesare P, Essiz M, Jacquet JP, Kiechel JR, Remuzon P, Weber A, Oki T, Masuyoshi M, Kessler RE, et al.

J Med Chem. 1990 May;33(5):1344-52.

PMID:
2329555
32.
33.

Binding of (+)-PN 200-110 to rat pituitaries and to normal and adenomatous human pituitaries.

Bression D, Chaumet-Riffaud P, Brandi AM, Comte A, Peillon F, Kiechel JR.

Mol Cell Endocrinol. 1987 Apr;50(3):255-61.

PMID:
3032711
34.
35.

[Pharmacokinetics and metabolism of cyclosporin; drug interactions].

Le Bigot JF, Lavene D, Kiechel JR.

Nephrologie. 1987;8(3):135-41. French.

PMID:
3658089
36.

[Reference values of chemical constituents and plasma enzymes in minipigs].

Hitz J, Devaux F, Galli F, Siest G, Kiechel JR.

Ann Biol Clin (Paris). 1987;45(5):532-6. French.

PMID:
3322115
37.

Impaired regulation of beta 2-adrenergic receptor density in mononuclear cells during chronic renal failure.

Souchet T, Brée F, Baatard R, Fontenaille C, D'Athis P, Tillement JP, Kiechel JR, Lhoste F.

Biochem Pharmacol. 1986 Aug 1;35(15):2513-9.

PMID:
3017355
38.
39.

Plasma protein binding and erythrocyte partitioning of nicardipine in vitro.

Urien S, Albengres E, Comte A, Kiechel JR, Tillement JP.

J Cardiovasc Pharmacol. 1985 Sep-Oct;7(5):891-8.

PMID:
2413297
40.

Hydergine pharmacokinetics in the elderly.

Lavène D, Humbert H, Kiechel JR, Ducreuzet C, Lajoie D, Guillevin L.

J Pharmacol. 1985;16 Suppl 3:135-43. English, French.

PMID:
4094443
41.

Nicardipine: pharmacokinetics and effects on carotid and brachial blood flows in normal volunteers.

Thuillez C, Gueret M, Duhaze P, Lhoste F, Kiechel JR, Giudicelli JF.

Br J Clin Pharmacol. 1984 Dec;18(6):837-47.

42.

[Pharmacokinetics: a contribution in clinical geriatric pharmacology?].

Kiechel JR, Lavène D, Humbert H.

Presse Med. 1983 Dec 29;12(48):3163-9. French.

PMID:
6228934
43.

Metabolism of ketotifen by human liver microsomes. In vitro characterization of a tertiary amine glucuronidation.

Le Bigot JF, Cresteil T, Kiechel JR, Beaune P.

Drug Metab Dispos. 1983 Nov-Dec;11(6):585-9.

PMID:
6140144
44.

Interaction of dihydroergotamine and triacetyloleandomycin in the minipig.

Martinet M, Kiechel JR.

Eur J Drug Metab Pharmacokinet. 1983 Jul-Sep;8(3):261-7.

PMID:
6606577
45.

Cultured human adult hepatocytes: a new model for drug metabolism studies.

Begue JM, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR, Guillouzo A.

Biochem Pharmacol. 1983 May 15;32(10):1643-6. No abstract available.

PMID:
6860350
46.

Quantification of ketotifen and its metabolites in human plasma by gas chromatography mass spectrometry.

Julien-Larose C, Guerret M, Lavene D, Kiechel JR.

Biomed Mass Spectrom. 1983 Mar;10(3):136-42.

PMID:
6850066
47.

Estimation of the absolute oral bioavailability of pindolol by two analytical methods.

Guerret M, Cheymol G, Aubry JP, Cheymol A, Lavene D, Kiechel JR.

Eur J Clin Pharmacol. 1983;25(3):357-9.

PMID:
6628523
48.

Pharmacokinetic aspects of guanfacine withdrawal syndrome in a hypertensive patient with chronic renal failure.

Kiechel JR, Lavene D, Guerret M, Comoy E, Godin M, Fillastre JP.

Eur J Clin Pharmacol. 1983;25(4):463-6.

PMID:
6360692
49.

Determination of 3-hydroxy-guanfacine in biological fluids by electron-capture gas-liquid chromatography.

Guerret M, Julien-Larose C, Kiechel JR, Lavène D.

J Chromatogr. 1982 Dec 10;233:181-92.

PMID:
6761349
50.

[Bioavailability of hydergine specific].

Kiechel JR, Lavène D, Humbert H, Guillaume MF.

Med Welt. 1982 Aug 27;33(34):1168-70. German. No abstract available.

PMID:
7132667

Supplemental Content

Loading ...
Support Center